Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | CCR1 | P32246 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | UBE2M | P61081 | 1/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3807493 | 1.00 | ABCB11 (1.00) | ABCB11CCR1MEN1BCHEACHE | |
| SCHEMBL3810728 | 1.00 | ABCB11 (1.00) | ABCB11CCR1MEN1BCHEACHE | |
| SCHEMBL3805756 | 0.93 | ABCB11 (0.87) | ABCB11CCR1BCHEACHEBACE1 | |
| SCHEMBL3805912 | 0.92 | ABCB11 (0.85) | ABCB11CCR1MEN1BCHEACHE | |
| SCHEMBL3807399 | 0.91 | ABCB11 (0.84) | ABCB11CCR1MEN1KMT2ASIGMAR1 | |
| SCHEMBL3813555 | 0.91 | ABCB11 (0.83) | ABCB11CCR1MEN1KMT2ASIGMAR1 | |
| SCHEMBL3809463 | 0.91 | ABCB11 (0.82) | ABCB11CCR1MEN1BCHEACHE | |
| SCHEMBL3807474 | 0.90 | CCR1 (0.83) | ABCB11CCR1MEN1KMT2ASIGMAR1 | |
| SCHEMBL1682975 | 0.90 | CCR1 (0.83) | ABCB11CCR1MEN1KMT2ASIGMAR1 | |
| SCHEMBL30172144 | 0.90 | CCR1 (0.83) | ABCB11CCR1MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306141-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| JP-4022142-B2 | — | — | 2007-12-12 | — | — | JP | claimed |
| CN-1307157-C | Novel compounds | ASTRAZENECA AB (SE) | 2007-03-28 | — | — | CN | claimed |
| US-6911458-B2 | Compounds | ASTRA ZENECA (SE) | 2005-06-28 | — | — | US | claimed |
| US-20050090494-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-04-28 | — | — | US | claimed |
| JP-2004507461-A | — | — | 2004-03-11 | — | — | JP | claimed |
| CN-1476434-A | Novel compounds | — | 2004-02-18 | — | — | CN | claimed |
| US-20030162772-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | claimed |
| EP-1299357-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | claimed |
| WO-2001098273-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | claimed |
| US-20090306141-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-7528156-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-05-05 | — | — | US | disclosed |
| CN-1307157-C | Novel compounds | ASTRAZENECA AB (SE) | 2007-03-28 | — | — | CN | disclosed |
| US-6911458-B2 | Compounds | ASTRA ZENECA (SE) | 2005-06-28 | — | — | US | disclosed |
| US-20050090494-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-04-28 | — | — | US | disclosed |
| CN-1476434-A | Novel compounds | — | 2004-02-18 | — | — | CN | disclosed |
| US-20030162772-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | disclosed |
| EP-1299357-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2001098273-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306141-A1 | Novel Compounds | CHRM2, CHRM1, C1R | ABCB11 113/4885CCR1 573/4885MEN1 61/4885 |
| US-20050090494-A1 | Novel compounds | CHRM2, CHRM1, C1R | ABCB11 113/4885CCR1 573/4885MEN1 61/4885 |
| US-20030162772-A1 | Novel compounds | RPS4X, RPS4Y1, MRPS18A | ABCB11 96/4885CCR1 505/4885MEN1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.